RxDoctor Payments Data

Gregory Warner, DO

Infectious Disease · Vacaville, CANPI 1073704326

Payments from drug & device makers

$708in general payments, 2019–2025

Across 31 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$98
  • AbbVie$79
  • Scilex Pharmaceuticals Inc.$62
  • Argenx US, Inc.$62
  • AstraZeneca$53
  • Lilly USA, LLC$50
  • plus $304 from 10 others

What the payments were for

  • Food & beverage$708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$708 in reported general payments places this provider in the 55th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$139,966
Medicare patients
317
Services billed
1,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala82$368,937
TivicayDolutegravir Sodium33$118,245
CabenuvaCabotegravir/Rilpivirine18$118,136
TriumeqAbacavir/Dolutegravir/Lamivudi23$104,590
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$82,872
DescovyEmtricitabine/Tenofov Alafenam20$65,839
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$61,958
IsentressRaltegravir Potassium25$57,539
JulucaDolutegravir/Rilpivirine12$39,323
Daptomycin45$21,082
Fosfomycin Tromethamine41$20,984
ErtapenemErtapenem Sodium31$9,315
Cefpodoxime Proxetil33$6,736
Doxycycline Monohydrate25$1,456
Fluconazole23$1,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Cabenuva, Triumeq, Juluca$98$380,29386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 856 infectious disease providers in California.

Other infectious disease in Vacaville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →